598P Can circulating PD-L1 levels, age at diagnosis and peritoneal carcinomatosis act as survival predictors in patients with advanced high-grade serous ovarian cancer?

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

“…In patients with ovarian cancer, elevated baseline sPD-1 associated with a shorter 5-year OS rate (median: 37 vs 49 months) in patients treated with surgery [24], and a shorter duration of PFS in patients treated with surgery or neoadjuvant chemotherapy [23]. Furthermore, among patients with high-grade serous ovarian cancer, elevated baseline sPD-1 correlated with shorter PFS (median: 24 vs 30 months) following combination treatment with surgery and chemotherapy [230].…”

“…Among epithelial ovarian cancer patients, high baseline sPD-L1 correlated with reduced PFS and OS 5 years after treatment with surgery and chemotherapy [60]. Elevated baseline sPD-L1 also correlated with shorter PFS (median: 24 vs 40 months) after combination treatment with surgery and chemotherapy in patients with highgrade serous ovarian cancer [230].…”

Investigating the association between genetically proxied circulating levels of immune checkpoint proteins and cancer survival: protocol for a Mendelian randomisation analysis

“…Although there is uncertainty over the prognostic value of blood-based measures, previous studies have found that higher circulating (ie, blood-based) PD-1 and PD-L1 levels are associated with poorer prognosis for patients diagnosed with cancer at different anatomical sites. For example, higher plasma soluble PD-1 and PD-L1 expression levels were associated with decreased progression-free survival for patients with advanced-stage high-grade serous ovarian cancer compared with those with lower PD-1 and PD-L1 expression 33. However, when accounting for other clinical factors in multivariable analyses, only soluble PD-L1 expression levels remained associated with progression-free survival for these patients 33.…”

“…For example, higher plasma soluble PD-1 and PD-L1 expression levels were associated with decreased progression-free survival for patients with advanced-stage high-grade serous ovarian cancer compared with those with lower PD-1 and PD-L1 expression 33. However, when accounting for other clinical factors in multivariable analyses, only soluble PD-L1 expression levels remained associated with progression-free survival for these patients 33. Higher circulating soluble PD-L1 expression was also associated with decreased overall and progression-free survival in a meta-analysis of patients with cancer at different anatomical sites, including non-small cell lung cancer and melanoma patients who had been treated with immunotherapy 34.…”

“…In contrast, although low serum exosomal PD-L1 expression was associated with increased median overall survival for pancreatic ductal adenocarcinoma patients compared with those with high exosomal PD-L1 expression, there was little statistical evidence to support this observed difference 35. Therefore, even though the prognostic roles of circulating PD-1 and PD-L1 expression levels have not been fully determined, there is some evidence supporting an association between blood-based measures of these immune checkpoint proteins and cancer survival, and the mechanism of action of these drugs is mediated by T cells 33–35…”